Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Ayala Pharmaceuticals, Inc. (GXPT) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Ayala Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1100397.
Total stock buying since 2014: $18,940,405.
Total stock sales since 2014: $10,804,362.
Total stock option exercises since 2014: $11,138,863.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 0 | $0 | 0 | $0 | 27,847,159 | $11,138,863 |
| 2023 | 1,317,716 | $0 | 0 | $0 | 0 | $0 |
| 2020 | 0 | $0 | 3,000 | $1,702 | 0 | $0 |
| 2019 | 3,000 | $11,391 | 0 | $0 | 0 | $0 |
| 2018 | 33,333 | $39,999 | 19,903 | $27,309 | 0 | $0 |
| 2017 | 0 | $0 | 1,874,745 | $8,180,653 | 0 | $0 |
| 2016 | 0 | $0 | 148,968 | $1,593,990 | 0 | $0 |
| 2015 | 1,484,762 | $18,889,015 | 80,758 | $962,466 | 0 | $0 |
| 2014 | 0 | $0 | 14,530 | $38,242 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-02 | 0 | $0 | 0 | $0 | 27,847,159 | $11,138,863 |
| 2023-10 | 1,317,716 | $0 | 0 | $0 | 0 | $0 |
| 2020-03 | 0 | $0 | 3,000 | $1,702 | 0 | $0 |
| 2019-04 | 3,000 | $11,391 | 0 | $0 | 0 | $0 |
| 2018-11 | 0 | $0 | 12,454 | $7,052 | 0 | $0 |
| 2018-09 | 33,333 | $39,999 | 0 | $0 | 0 | $0 |
| 2018-04 | 0 | $0 | 2,193 | $3,552 | 0 | $0 |
| 2018-02 | 0 | $0 | 32 | $93 | 0 | $0 |
| 2018-01 | 0 | $0 | 5,224 | $16,612 | 0 | $0 |
| 2017-11 | 0 | $0 | 32,968 | $105,999 | 0 | $0 |
| 2017-10 | 0 | $0 | 600,000 | $2,580,000 | 0 | $0 |
| 2017-09 | 0 | $0 | 1,239,323 | $5,474,434 | 0 | $0 |
| 2017-03 | 0 | $0 | 2,454 | $20,220 | 0 | $0 |
| 2016-12 | 0 | $0 | 17,836 | $140,195 | 0 | $0 |
| 2016-11 | 0 | $0 | 11,037 | $91,827 | 0 | $0 |
| 2016-10 | 0 | $0 | 19,162 | $157,703 | 0 | $0 |
| 2016-08 | 0 | $0 | 56,569 | $863,101 | 0 | $0 |
| 2016-05 | 0 | $0 | 15,122 | $113,319 | 0 | $0 |
| 2016-03 | 0 | $0 | 17,325 | $145,857 | 0 | $0 |
| 2016-01 | 0 | $0 | 11,917 | $81,988 | 0 | $0 |
| 2015-12 | 0 | $0 | 14,332 | $177,573 | 0 | $0 |
| 2015-10 | 0 | $0 | 55,034 | $609,002 | 0 | $0 |
| 2015-08 | 300,000 | $4,253,300 | 0 | $0 | 0 | $0 |
| 2015-07 | 0 | $0 | 11,392 | $175,891 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-02-07 | I.b.f. Management Ltd. | Option Ex | 27,847,159 | .40 | 11,138,863 |
| 2023-10-18 | I.b.f. Management Ltd. | Buy | 1,317,716 | .00 | 0 |
| 2020-03-13 | Appel Roni | Sale | 2,401 | .55 | 1,320 |
| 2020-03-12 | Appel Roni | Sale | 200 | .58 | 115 |
| 2020-03-11 | Appel Roni | Sale | 399 | .67 | 267 |
| 2019-04-10 | Appel Roni | Buy | 3,000 | 3.80 | 11,391 |
| 2018-11-05 | Petit Robert (Chief Scientific Officer) | Sale | 3,963 | .58 | 2,298 |
| 2018-11-02 | Petit Robert (Chief Scientific Officer) | Sale | 8,491 | .56 | 4,754 |
| 2018-09-11 | Appel Roni | Buy | 33,333 | 1.20 | 39,999 |
| 2018-04-02 | Petit Robert (Chief Scientific Officer) | Sale | 2,193 | 1.62 | 3,552 |
| 2018-02-02 | Lombardo Anthony A (Interim CEO) | Sale | 32 | 2.93 | 93 |
| 2018-01-03 | Bonstein Sara (Chief Financial Officer) | Sale | 5,224 | 3.18 | 16,612 |
| 2017-11-06 | Bonstein Sara (Chief Financial Officer) | Sale | 3,862 | 3.30 | 12,744 |
| 2017-11-06 | Petit Robert (Chief Scientific Officer) | Sale | 3,723 | 3.30 | 12,285 |
| 2017-11-02 | Bonstein Sara (Chief Financial Officer) | Sale | 12,734 | 3.19 | 40,621 |
| 2017-11-02 | Petit Robert (Chief Scientific Officer) | Sale | 12,625 | 3.19 | 40,273 |
| 2017-11-02 | Lombardo Anthony A (Interim CEO) | Sale | 24 | 3.19 | 76 |
| 2017-10-11 | Gross Phillip | Sale | 600,000 | 4.30 | 2,580,000 |
| 2017-09-26 | Gross Phillip | Sale | 300,000 | 4.00 | 1,200,000 |
| 2017-09-25 | Gross Phillip | Sale | 405,323 | 4.38 | 1,775,314 |
| 2017-09-22 | Gross Phillip | Sale | 534,000 | 4.68 | 2,499,120 |
| 2017-03-31 | Petit Robert (Chief Scientific Officer) | Sale | 2,454 | 8.24 | 20,220 |
| 2016-12-30 | Bonstein Sara (Chief Financial Officer) | Sale | 5,520 | 7.37 | 40,682 |
| 2016-12-20 | Mckearn Thomas J | Sale | 12,316 | 8.08 | 99,513 |
| 2016-11-02 | Petit Robert (Chief Scientific Officer) | Sale | 2,797 | 8.32 | 23,271 |
| 2016-11-02 | O'connor Daniel (Chief Executive Officer) | Sale | 8,240 | 8.32 | 68,556 |
| 2016-10-25 | Mayes, Gregory T. (Chief Business Officer) | Sale | 19,162 | 8.23 | 157,703 |
| 2016-08-09 | Sidransky David | Sale | 11,404 | 14.85 | 169,349 |
| 2016-08-09 | Berman Richard J | Sale | 15,761 | 15.67 | 246,974 |
| 2016-08-08 | Sidransky David | Sale | 11,404 | 15.17 | 172,998 |
| 2016-08-08 | Berman Richard J | Sale | 18,000 | 15.21 | 273,780 |
| 2016-05-13 | Mckearn Thomas J | Sale | 4,100 | 7.45 | 30,545 |
| 2016-05-02 | Petit Robert (Chief Scientific Officer) | Sale | 2,785 | 7.51 | 20,915 |
| 2016-05-02 | O'connor Daniel (Chief Executive Officer) | Sale | 8,237 | 7.51 | 61,859 |
| 2016-03-31 | Petit Robert (Chief Scientific Officer) | Sale | 3,325 | 9.13 | 30,357 |
| 2016-03-16 | Mckearn Thomas J | Sale | 14,000 | 8.25 | 115,500 |
| 2016-01-29 | Petit Robert (Chief Scientific Officer) | Sale | 3,099 | 6.88 | 21,321 |
| 2016-01-29 | O'connor Daniel (Chief Executive Officer) | Sale | 8,818 | 6.88 | 60,667 |
| 2015-12-17 | Berman Richard J | Sale | 14,332 | 12.39 | 177,573 |
| 2015-10-30 | Petit Robert (Chief Scientific Officer) | Sale | 2,867 | 12.26 | 35,149 |
| 2015-10-30 | O'connor Daniel (Chief Executive Officer) | Sale | 8,350 | 12.26 | 102,371 |
| 2015-10-26 | Mayes, Gregory T. (Chief Operating Officer) | Sale | 19,231 | 11.63 | 223,656 |
| 2015-10-20 | Mauro David J (Chief Medical Officer) | Sale | 24,586 | 10.08 | 247,826 |
| 2015-08-24 | Gross Phillip | Buy | 50,000 | 13.81 | 690,300 |
| 2015-08-21 | Gross Phillip | Buy | 75,000 | 14.21 | 1,065,750 |
| 2015-08-20 | Gross Phillip | Buy | 175,000 | 14.27 | 2,497,250 |
| 2015-07-31 | Petit Robert (Chief Scientific Officer) | Sale | 2,943 | 15.44 | 45,439 |
| 2015-07-31 | O'connor Daniel (Chief Executive Officer) | Sale | 8,449 | 15.44 | 130,452 |
| 2015-04-30 | Gross Phillip | Buy | 500,000 | 19.00 | 9,500,000 |
| 2015-02-18 | Gross Phillip | Buy | 684,762 | 7.50 | 5,135,715 |
| 2014-05-09 | Berman Richard J | Sale | 14,530 | 2.63 | 38,242 |
Insider trading activities including stock purchases, stock sales, and option exercises of GXPT listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Ayala Pharmaceuticals, Inc. (symbol GXPT, CIK number 1100397) see the Securities and Exchange Commission (SEC) website.